Avantra said that TD2's pharma clients could use its platform to identify appropriate biomarkers for use with drugs in development.

New Product Watch


Avantra Biosciences' Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay, Akonni Biosystems' TruSentry System, Agilent Technologies' BenchBot Robot, Exiqon's Mircury LNA microRNA Labeling Kits

Avantra was founded last year by Courtagen Capital Group to commercialize the assets of Decision Biomarkers, a protein biomarker technology firm that shuttered its business and filed for Chapter 7 bankruptcy in December 2009.

Formed from what had been Decision Biomarkers, Avantra is eyeing a launch of its biomarker detection platform in early 2011.

The company is being launched by Courtagen Capital Group using assets from defunct biotech firm Decision Biomarkers, which Courtagen purchased in bankruptcy court last December.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.